Kapil Dhingra, a director at Replimune Group, Inc. ($REPL), made one open market sale of common shares in the last year, totaling nearly $33,000. His most recent $REPL insider sale occurred on December 9, 2025. This ranks 10,740th among 11,678 insiders by sales value, well below the average of $8.6 million across 6.4 transactions. Dhingra reported no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec. 9, 2025 | Replimune Group, Inc. | $REPL | Dhingra Kapil | Director | M | Common Stock | 3169 | $1.75 | 3,169.0000 | 91,915,769 | 9999.99% | 0.00% |
| Dec. 9, 2025 | Replimune Group, Inc. | $REPL | Dhingra Kapil | Director | M | Stock Option (right to buy) | 3169 | $0.00 | 0.0000 | 91,915,769 | 100.00% | 0.00% |
| Dec. 9, 2025 | Replimune Group, Inc. | $REPL | Dhingra Kapil | Director | S | Common Stock | 3169 | $10.40 | 0.0000 | 91,915,769 | 100.00% | 0.00% |
| Nov. 13, 2025 | LAVA Therapeutics NV | $LVTX | Dhingra Kapil | Not found | D | Common Shares | 30000 | $0.00 | 0.0000 | 26,899,122 | 100.00% | 0.11% |
| Nov. 13, 2025 | LAVA Therapeutics NV | $LVTX | Dhingra Kapil | Not found | D | Share Options (Right to Buy) | 33390 | $0.00 | 0.0000 | 26,899,122 | 100.00% | 0.12% |
| Aug. 19, 2025 | CARGO Therapeutics, Inc. | $CRGX | Dhingra Kapil | Not found | D | Stock Option (Right to Buy) | 25000 | $0.00 | 0.0000 | 48,364,311 | 100.00% | 0.05% |
| June 18, 2025 | CARGO Therapeutics, Inc. | $CRGX | Dhingra Kapil | Not found | A | Stock Option (Right to Buy) | 25000 | $0.00 | 25,000.0000 | 46,052,368 | 9999.99% | 0.05% |
| June 12, 2025 | Black Diamond Therapeutics, Inc. | $BDTX | Dhingra Kapil | Not found | A | Stock Option (Right to Buy) | 30550 | $0.00 | 30,550.0000 | 55,028,371 | 9999.99% | 0.06% |
| April 1, 2025 | Replimune Group, Inc. | $REPL | Dhingra Kapil | Director | A | Stock Option (right to buy) | 32000 | $0.00 | 32,000.0000 | 80,564,147 | 9999.99% | 0.04% |
| Feb. 13, 2025 | LAVA Therapeutics NV | $LVTX | Dhingra Kapil | Not found | A | Common Shares (Right to Buy) | 33390 | $0.00 | 33,390.0000 | 26,834,422 | 9999.99% | 0.12% |
| June 6, 2024 | Black Diamond Therapeutics, Inc. | $BDTX | Dhingra Kapil | Not found | A | Stock Option (Right to Buy) | 30550 | $0.00 | 30,550.0000 | 43,954,649 | 9999.99% | 0.07% |
| June 4, 2024 | CARGO Therapeutics, Inc. | $CRGX | Dhingra Kapil | Not found | A | Stock Option (Right to Buy) | 11871 | $0.00 | 11,871.0000 | 0 | 9999.99% | 0.00% |
| April 15, 2024 | CARGO Therapeutics, Inc. | $CRGX | Dhingra Kapil | Not found | A | Stock Option (Right to Buy) | 49265 | $0.00 | 49,265.0000 | 0 | 9999.99% | 0.00% |
| April 1, 2024 | Replimune Group, Inc. | $REPL | Dhingra Kapil | Director | A | Stock Option (right to buy) | 32000 | $0.00 | 32,000.0000 | 66,569,894 | 9999.99% | 0.05% |